Media coverage about NewLink Genetics (NASDAQ:NLNK) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NewLink Genetics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.110683955238 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

NLNK traded down $0.08 during trading on Friday, reaching $3.01. 408,871 shares of the company traded hands, compared to its average volume of 528,227. NewLink Genetics has a 12-month low of $2.90 and a 12-month high of $19.30. The firm has a market cap of $114.99 million, a P/E ratio of -1.31 and a beta of 1.37.

NewLink Genetics (NASDAQ:NLNK) last issued its earnings results on Tuesday, July 31st. The biotechnology company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.12. The company had revenue of $2.25 million for the quarter, compared to the consensus estimate of $5.85 million. NewLink Genetics had a negative net margin of 252.18% and a negative return on equity of 53.70%. equities research analysts expect that NewLink Genetics will post -1.69 EPS for the current year.

Several research firms have recently commented on NLNK. Cantor Fitzgerald set a $7.00 target price on NewLink Genetics and gave the company a “hold” rating in a report on Monday, April 16th. ValuEngine upgraded NewLink Genetics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Stifel Nicolaus reduced their price objective on NewLink Genetics from $21.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, May 4th. Finally, Zacks Investment Research upgraded NewLink Genetics from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research note on Saturday, May 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $9.64.

In other news, Director Ernest Talarico III sold 13,806 shares of NewLink Genetics stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $4.82, for a total transaction of $66,544.92. Following the completion of the sale, the director now directly owns 39,365 shares in the company, valued at $189,739.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 12.30% of the stock is owned by company insiders.

NewLink Genetics Company Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Featured Article: Are analyst ratings accurate?

Insider Buying and Selling by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.